Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy
about
Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice.Pattern and prognostic value of cardiac involvement in patients with late-onset pompe disease: a comprehensive cardiovascular magnetic resonance approach.Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease.Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes.Toward deconstructing the phenotype of late-onset Pompe disease.Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient.[Diagnosis and therapy of late onset Pompe disease].S1.4 Cardiovascular involvement in Pompedisease.Cardiac response to enzyme replacement therapy in infantile Pompe disease with severe hypertrophic cardiomyopathy.Structural and functional cardiac analyses using modern and sensitive myocardial techniques in adult Pompe disease.Correction of a short cardiac PR interval in a 12-year-old girl with late-onset Pompe disease following enzyme replacement therapy.Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.Right ventricular function in late-onset Pompe disease.Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.Chagasic cardiomyopathy and Pompe disease: case report.
P2860
Q34388932-CAFA8EEF-AC32-4B1B-B5F7-B1FCDE64EAB4Q37488016-DCFF40AD-D2BE-42AF-83E5-5E3FF8AEA369Q37976637-12269F2B-E1D6-44C8-BB2B-ABE33A58BC96Q38675468-689366AE-3AB7-4AC7-86E3-0FA45F05E4E8Q39345477-9DFA7A53-B30E-4C65-A9E0-20BF02A4F8E0Q39663459-64EBF85C-CDC2-43AE-8F08-B61028796E1BQ41229793-F27CBFBF-A729-413F-B64B-738B7E6AB5B7Q44767256-CCED6F03-68CC-430A-A656-6E311B72EFF3Q46902276-BC440F5D-7477-46ED-8BE9-BC1941EC6F4FQ48156080-9BB6BD0F-D363-4732-B063-357591F73016Q48681869-E60CEEF2-F2F6-46F0-AF23-FA22AC939ACDQ49106247-A87459E0-5551-432A-A59D-B3DB43F7E222Q50790826-D53B5838-91C1-4517-9298-D2A80612AF29Q51123845-C275EA8C-CCF4-4333-B136-06BBC5B4F000Q54310178-23B60ED8-8585-457B-8C75-3E86062612EDQ54985902-1E498BEC-4DC2-4C5D-8209-C51A97BD629E
P2860
Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cardiovascular abnormalities i ...... to enzyme replacement therapy
@ast
Cardiovascular abnormalities i ...... to enzyme replacement therapy
@en
Cardiovascular abnormalities i ...... to enzyme replacement therapy
@nl
type
label
Cardiovascular abnormalities i ...... to enzyme replacement therapy
@ast
Cardiovascular abnormalities i ...... to enzyme replacement therapy
@en
Cardiovascular abnormalities i ...... to enzyme replacement therapy
@nl
prefLabel
Cardiovascular abnormalities i ...... to enzyme replacement therapy
@ast
Cardiovascular abnormalities i ...... to enzyme replacement therapy
@en
Cardiovascular abnormalities i ...... to enzyme replacement therapy
@nl
P2093
P2860
P1433
P1476
Cardiovascular abnormalities i ...... to enzyme replacement therapy
@en
P2093
Ans T van der Ploeg
Jennifer S Li
Late-Onset Treatment Study Investigators
P Brian Smith
Priya Kishnani
Sara K Pasquali
P2860
P2888
P304
P356
10.1097/GIM.0B013E3182142966
P407
P577
2011-07-01T00:00:00Z
P6179
1014082474